Healthcare Industry Developments | BioTuesdays by Kilmer Lucas IR

Developments

CervoMed reports new data from trial showing potential of neflamapimod for DLB

CervoMed (NASDAQ: CRVO) has announced additional data from its Phase 2b RewinD-LB trial, demonstrating neflamapimod’s potential as a treatment for dementia with Lewy bodies (DLB). According to CervoMed, FDA feedback on...

October 8, 2025

Developments

USPTO grants Aquestive two patents for Anaphylm

Aquestive Therapeutics (NASDAQ: AQST) has announced that the USPTO has issued two additional patents extending protection into 2037 for Anaphylm, a novel epinephrine prodrug sublingual film. According to Aquestive, if...

October 8, 2025

Developments

Profound sees record revenues in Q3-2025; up 84-87% YoY with higher gross margin

Profound Medical (NASDAQ: PROF; TSX: PRN) announced that it anticipates total revenues for the third quarter of 2025 to be in the approximate range of $5.2 million to $5.3 million, representing YoY revenue growth of...

October 7, 2025

Developments

PharmaJet initiates development of needle-free injection pens for home use

Closely held PharmaJet has announced that it is expanding its needle-free injection portfolio with the development of a suite of proprietary, needle-free, self-injector pens. The single-use and reusable needle-free...

October 7, 2025

Developments

FDA grants ALTO fast track designation for treatment of CIAS

Alto Neuroscience (NYSE: ANRO) announced that the FDA has granted its novel small molecule PDE4 inhibitor, ALTO-101, fast track designation for the treatment of cognitive impairment associated with schizophrenia (CIAS)...

October 6, 2025

Developments

Aspire files omnibus patent application with USPTO for drug delivery platform

Aspire Biopharma Holdings (NASDAQ: ASBP) has announced the filing of an omnibus patent application with the USPTO for its sublingual drug delivery technology. According to Aspire, the technology is designed to enhance...

October 6, 2025

Developments

First patient dosed in Perspective’s study of PSV359 in FAP-a positive solid tumors

Perspective Therapeutics (NYSE American: CATX) has announced that the first patient has been dosed in the second cohort of a Phase 1/2a dose-finding trial to determine the safety and preliminary anti-tumor activity of...

October 2, 2025

Developments

Profusa adds leading CLTI surgeon to customer base

Profusa (NASDAQ: PFSA) has announced that Yann Gouëffic, MD, PhD, professor of vascular surgery in the Vascular Center at Groupe Hospitalier Paris Saint Joseph, Paris, France will adopt the company’s Lumee oxygen...

October 1, 2025

Developments

Larimar reports positive data from study of nomlabofusp in FA

Larimar Therapeutics (NASDAQ: LRMR) has announced positive 25 mg and 50 mg data from the ongoing long-term open label (OL) study evaluating daily subcutaneous injections of nomlabofusp self-administered or administered...

September 30, 2025

Developments

Anebulo announces first dose in SAD study of IV selonabant for ACI

Anebulo Pharmaceuticals (NASDAQ: ANEB) has announced first patients dosed in its Phase 1 single ascending dose (SAD) study intravenous selonabant—under development for acute cannabis-induced (ACI) toxicity—in healthy...

September 26, 2025

Developments

ME secures U.S. patent for lead G-CSF antibody candidate

Me Therapeutics Holdings (CSE: METX; FSE: Q9T) has announced that the United States Patent Office (USPTO) has granted its subsidiary, ME Therapeutics, a patent for its lead G-CSF antibody candidate. According to ME, the...

September 26, 2025

Developments

USPTO grants Nexalin patent for next-gen HALO Clarity device

Nexalin Technology (NASDAQ: NXL; NXLIW) has announced that the United States Patent and Trademark Office (USPTO) has issued a design patent providing 15 years of protection for the company’s next-generation HALO Clarity...

September 25, 2025

Developments

CIPO grants NOA to Moleculin for patent covering Annamycin

Moleculin Biotech (NASDAQ: MBRX) announced that the Canadian Intellectual Property Office (CIPO) has issued a notice of allowance (NOA) for a patent covering methods of making a preliposomal Annamycin lyophilizate with...

September 25, 2025

Developments

TGA approves MediWound’s NexoBrid for burn management in Australia

MediWound (NASDAQ: MDWD) has announced that Australia’s Therapeutic Goods Administration (TGA) has granted marketing authorization for NexoBrid—an enzymatic therapy for the removal of eschar in both adult and pediatric...

September 25, 2025

Developments

GeoVax expands with additional solid tumor targets for Gedeptin

GeoVax Labs (NASDAQ: GOVX) has announced the expansion of its oncology development strategy to evaluate additional solid tumor targets for Gedeptin—its gene-directed enzyme prodrug therapy. According to GeoVax, the...

September 24, 2025

Developments

IGC announces pre-clinical data for TGR-63 in AD

IGC Pharma (NYSE: IGC) has announced preclinical findings on its investigational small molecule candidate for Alzheimer’s disease (AD) demonstrating that TGR-63 extends its therapeutic potential beyond previously...

September 24, 2025

Developments

Hemogenyx, Cellin sign LOI to commercialize cell therapy for R/R AML in Estonia

Hemogenyx Pharmaceuticals (LSE: HEMO) has announced the signing of a letter of intent (LOI) with closely held Cellin Technologies to explore the commercialization of its HG-CT-1 CAR-T cell therapy for the treatment of...

September 23, 2025

Developments

EC and Swissmedic approve KalVista’s oral treatment for HAE

KalVista Pharmaceuticals (NASDAQ: KALV) announced that the European Commission (EC) and Swiss Agency for Therapeutic Products (Swissmedic) have approved EKTERLY (sebetralstat), a novel, oral plasma kallikrein inhibitor...

September 19, 2025

Developments

Palisade announces positive PALI-2108 data

Palisade Bio (NASDAQ: PALI) has announced new data from its ongoing clinical program evaluating PALI-2108, a first-in-class, ileocolonic-targeted PDE4 B/D inhibitor. The company plans to present the results in an oral...

September 17, 2025

Developments

Vivos unveils landmark trial results in pediatric OSA treatment

Vivos Therapeutics (NASDAQ: VVOS) has announced first time, peer-reviewed published data confirming that the Vivos Daytime-Nighttime Appliance (DNA) is both safe and efficacious in treating children suffering from...

September 17, 2025

Developments

FDA grants Corbus fast track designation for CRB-701 in HNSCC

Corbus Pharmaceuticals (NASDAQ: CRBP) has announced that the FDA has granted fast track designation to its next-generation Nectin-4 antibody drug conjugate CRB-701 for the treatment of recurrent or metastatic head and...

September 16, 2025

Developments

Adagene, Exelixis amend license agreement to develop third masked mAb

Adagene (NASDAQ: ADAG) has announced an amendment to the 2021 collaboration and license agreement with Exelixis (Nasdaq: EXEL) to enable the development of a third novel masked monoclonal antibody (mAb) drug conjugate...

September 16, 2025

Subscribe